These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 36202389)

  • 1. Discovery, Chemistry, and Preclinical Development of Pritelivir, a Novel Treatment Option for Acyclovir-Resistant Herpes Simplex Virus Infections.
    Birkmann A; Bonsmann S; Kropeit D; Pfaff T; Rangaraju M; Sumner M; Timmler B; Zimmermann H; Buschmann H; Ruebsamen-Schaeff H
    J Med Chem; 2022 Oct; 65(20):13614-13628. PubMed ID: 36202389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Helicase-primase as a target of new therapies for herpes simplex virus infections.
    James SH; Larson KB; Acosta EP; Prichard MN
    Clin Pharmacol Ther; 2015 Jan; 97(1):66-78. PubMed ID: 25670384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of pritelivir and acyclovir in the treatment of herpes simplex virus infections in a mouse model of herpes simplex encephalitis.
    Quenelle DC; Birkmann A; Goldner T; Pfaff T; Zimmermann H; Bonsmann S; Collins DJ; Rice TL; Prichard MN
    Antiviral Res; 2018 Jan; 149():1-6. PubMed ID: 29113740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics-pharmacodynamics of the helicase-primase inhibitor pritelivir following treatment of wild-type or pritelivir-resistant virus infection in a murine herpes simplex virus 1 infection model.
    Biswas S; Sukla S; Goldner T; Field HJ; Kropeit D; Paulsen D; Welbers A; Ruebsamen-Schaeff H; Zimmermann H; Birkmann A
    Antimicrob Agents Chemother; 2014 Jul; 58(7):3843-52. PubMed ID: 24752278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral bioavailability and in vivo efficacy of the helicase-primase inhibitor BILS 45 BS against acyclovir-resistant herpes simplex virus type 1.
    Duan J; Liuzzi M; Paris W; Liard F; Browne A; Dansereau N; Simoneau B; Faucher AM; Cordingley MG
    Antimicrob Agents Chemother; 2003 Jun; 47(6):1798-804. PubMed ID: 12760851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiviral agents for herpes simplex virus.
    Vere Hodge RA; Field HJ
    Adv Pharmacol; 2013; 67():1-38. PubMed ID: 23885997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Helicase-primase inhibitors from Medshine Discovery Inc. (WO2018/127207 and WO2020/007355) for the treatment of herpes simplex virus infections - structure proposal for Phaeno Therapeutics drug candidate HN0037.
    Gege C; Kleymann G
    Expert Opin Ther Pat; 2022 Sep; 32(9):933-937. PubMed ID: 35965439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Preclinical Model for Studying Herpes Simplex Virus Infection.
    Tajpara P; Mildner M; Schmidt R; Vierhapper M; Matiasek J; Popow-Kraupp T; Schuster C; Elbe-Bürger A
    J Invest Dermatol; 2019 Mar; 139(3):673-682. PubMed ID: 30414908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HSV antivirals - current and future treatment options.
    Birkmann A; Zimmermann H
    Curr Opin Virol; 2016 Jun; 18():9-13. PubMed ID: 26897058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of pritelivir in refractory aciclovir-resistant herpes simplex virus type 2.
    Cannon L; Tholouli E; Ward C; Farooq H; Kingston M
    Int J STD AIDS; 2021 Sep; 32(10):978-980. PubMed ID: 33947276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current and future therapies for herpes simplex virus infections: mechanism of action and drug resistance.
    James SH; Prichard MN
    Curr Opin Virol; 2014 Oct; 8():54-61. PubMed ID: 25036916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Helicase primase inhibitors (HPIs) are efficacious for therapy of human herpes simplex virus (HSV) disease in an infection mouse model.
    Uhlig N; Donner AK; Gege C; Lange F; Kleymann G; Grunwald T
    Antiviral Res; 2021 Nov; 195():105190. PubMed ID: 34666109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High conservation of herpes simplex virus UL5/UL52 helicase-primase complex in the era of new antiviral therapies.
    Collot M; Rouard C; Brunet C; Agut H; Boutolleau D; Burrel S
    Antiviral Res; 2016 Apr; 128():1-6. PubMed ID: 26826441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Baseline sensitivity of HSV-1 and HSV-2 clinical isolates and defined acyclovir-resistant strains to the helicase-primase inhibitor pritelivir.
    Field HJ; Huang ML; Lay EM; Mickleburgh I; Zimmermann H; Birkmann A
    Antiviral Res; 2013 Nov; 100(2):297-9. PubMed ID: 24021190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease.
    Crute JJ; Grygon CA; Hargrave KD; Simoneau B; Faucher AM; Bolger G; Kibler P; Liuzzi M; Cordingley MG
    Nat Med; 2002 Apr; 8(4):386-91. PubMed ID: 11927945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acyclovir resistance in herpes simplex viruses: Prevalence and therapeutic alternatives.
    Schalkwijk HH; Snoeck R; Andrei G
    Biochem Pharmacol; 2022 Dec; 206():115322. PubMed ID: 36309081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance of herpes simplex virus infections to nucleoside analogues in HIV-infected patients.
    Levin MJ; Bacon TH; Leary JJ
    Clin Infect Dis; 2004 Nov; 39 Suppl 5():S248-57. PubMed ID: 15494896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease.
    Kleymann G; Fischer R; Betz UA; Hendrix M; Bender W; Schneider U; Handke G; Eckenberg P; Hewlett G; Pevzner V; Baumeister J; Weber O; Henninger K; Keldenich J; Jensen A; Kolb J; Bach U; Popp A; Mäben J; Frappa I; Haebich D; Lockhoff O; Rübsamen-Waigmann H
    Nat Med; 2002 Apr; 8(4):392-8. PubMed ID: 11927946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Pritelivir Compared With Valacyclovir on Genital HSV-2 Shedding in Patients With Frequent Recurrences: A Randomized Clinical Trial.
    Wald A; Timmler B; Magaret A; Warren T; Tyring S; Johnston C; Fife K; Selke S; Huang ML; Stobernack HP; Zimmermann H; Corey L; Birkmann A; Ruebsamen-Schaeff H
    JAMA; 2016 Dec; 316(23):2495-2503. PubMed ID: 27997653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Herpes simplex virus resistance to acyclovir: clinical relevance.
    Pottage JC; Kessler HA
    Infect Agents Dis; 1995 Sep; 4(3):115-24. PubMed ID: 8548189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.